Adverum Biotechnologies (ADVM) Competitors

In the previous week, Avalo Therapeutics had 15 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 15 mentions for Avalo Therapeutics and 0 mentions for Adverum Biotechnologies. Avalo Therapeutics' average media sentiment score of 0.58 beat Adverum Biotechnologies' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Avalo Therapeutics' return on equity of -77.91% beat Adverum Biotechnologies' return on equity.

Avalo Therapeutics presently has a consensus price target of $47.83, suggesting a potential upside of 194.18%. Adverum Biotechnologies has a consensus price target of $10.50, suggesting a potential upside of 140.83%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Avalo Therapeutics is more favorable than Adverum Biotechnologies.

Avalo Therapeutics has higher revenue and earnings than Adverum Biotechnologies. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Comparatively, 6.0% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Avalo Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

In the previous week, Akebia Therapeutics had 5 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 5 mentions for Akebia Therapeutics and 0 mentions for Adverum Biotechnologies. Akebia Therapeutics' average media sentiment score of 0.29 beat Adverum Biotechnologies' score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Adverum Biotechnologies has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -2.26%. Akebia Therapeutics' return on equity of -16.70% beat Adverum Biotechnologies' return on equity.

Akebia Therapeutics presently has a consensus price target of $4.67, suggesting a potential upside of 221.84%. Adverum Biotechnologies has a consensus price target of $10.50, suggesting a potential upside of 140.83%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Akebia Therapeutics is more favorable than Adverum Biotechnologies.

Akebia Therapeutics has higher revenue and earnings than Adverum Biotechnologies. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 3.0% of Akebia Therapeutics shares are held by insiders. Comparatively, 6.0% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Akebia Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 1 mentions for Rocket Pharmaceuticals and 0 mentions for Adverum Biotechnologies. Rocket Pharmaceuticals' average media sentiment score of 0.00 equaled Adverum Biotechnologies'average media sentiment score.

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 6.0% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rocket Pharmaceuticals' return on equity of -64.74% beat Adverum Biotechnologies' return on equity.

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Rocket Pharmaceuticals presently has a consensus price target of $13.86, suggesting a potential upside of 291.44%. Adverum Biotechnologies has a consensus price target of $10.50, suggesting a potential upside of 140.83%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Adverum Biotechnologies.

Rocket Pharmaceuticals has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Forte Biosciences is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Forte Biosciences presently has a consensus price target of $67.00, suggesting a potential upside of 145.51%. Adverum Biotechnologies has a consensus price target of $10.50, suggesting a potential upside of 140.83%. Given Forte Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Forte Biosciences is more favorable than Adverum Biotechnologies.

In the previous week, Forte Biosciences had 3 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 3 mentions for Forte Biosciences and 0 mentions for Adverum Biotechnologies. Forte Biosciences' average media sentiment score of 1.11 beat Adverum Biotechnologies' score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the media.

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by insiders. Comparatively, 6.0% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Forte Biosciences' return on equity of -98.36% beat Adverum Biotechnologies' return on equity.

Forte Biosciences has a beta of 3.01, meaning that its stock price is 201% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.